Tabula Rasa HealthCare (Nasdaq:TRHC) - Aandelenkoers, Nieuws & Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

TRHC Overzicht aandelen

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States.

TRHC fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 13.23% per jaar groeien

Risicoanalyse

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Tabula Rasa HealthCare, Inc. Concurrenten

TruBridge

NasdaqGS:TBRG

US$186.3m

Health Catalyst

NasdaqGS:HCAT

US$465.6m

SOPHiA GENETICS

NasdaqGS:SOPH

US$241.0m

Sharecare

NasdaqGS:SHCR

US$533.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Tabula Rasa HealthCare
Historische aandelenkoersen
Huidige aandelenkoers	US$10.50
52 Week Hoogtepunt	US$10.50
52 Week Laag	US$3.15
Bèta	1.58
11 maand verandering	1.16%
3 maanden verandering	34.10%
1 Jaar Verandering	203.47%
33 jaar verandering	-70.13%
5 jaar verandering	-85.61%
Verandering sinds IPO	-29.44%

Recent nieuws en updates

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

Rendement voor aandeelhouders

	TRHC	US Healthcare Services	US Markt
7D	0.9%	0.8%	-1.2%
1Y	203.5%	2.0%	30.6%

Rendement versus industrie: TRHC overtrof de US Healthcare Services industrie, die het afgelopen jaar een rendement 2 % opleverde.

Rendement versus markt: TRHC overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.6 %.

Prijsvolatiliteit

Is TRHC's price volatile compared to industry and market?
TRHC volatility
TRHC Average Weekly Movement	8.6%
Healthcare Services Industry Average Movement	8.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van TRHC is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van TRHC is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	1,027	Brian Adams	www.tabularasahealthcare.com

Tabula Rasa HealthCare, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Tabula Rasa HealthCare zich tot de beurswaarde?
TRHC fundamentele statistieken
Marktkapitalisatie	US$284.03m
Inkomsten(TTM)	-US$61.07m
Inkomsten(TTM)	US$338.12m

0.8x

P/S-verhouding

-4.7x

Koers/Winstverhouding

Is TRHC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TRHC resultatenrekening (TTM)
Inkomsten	US$338.12m
Kosten van inkomsten	US$258.28m
Brutowinst	US$79.84m
Overige uitgaven	US$140.91m
Inkomsten	-US$61.07m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.26
Brutomarge	23.61%
Nettowinstmarge	-18.06%
Schuld/Eigen Vermogen Verhouding	-418.7%

Hoe presteerde TRHC op de lange termijn?

Bekijk historische prestaties en vergelijking

This company has been acquired

TRHC Overzicht aandelen

Beloningen

Risicoanalyse

Tabula Rasa HealthCare, Inc. Concurrenten

NasdaqGS:TBRG

US$186.3m

NasdaqGS:HCAT

US$465.6m

NasdaqGS:SOPH

US$241.0m

NasdaqGS:SHCR

US$533.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching